Standard BioTools Inc. Common Stock (LAB) — Analysis Summary
Standard BioTools Inc. Common Stock (LAB) has a market cap of $258.24M with year-over-year revenue growth of -51.1%. Net margin stands at -87.8%. The stock trades at a P/E ratio of 3.0.
Key Takeaways
- Revenue changed -51.1% year-over-year
- Net margin of -87.8%
- P/E ratio of 3.0
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, LAB posted revenue growth of -51.1% and trades at a P/E of 3.0.
Standard BioTools Inc. Common Stock (LAB)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -112.8% — severe operating losses
The latest filing shows negative free cash flow.
Operating cash flow is negative while net income remains positive.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
389
Headquarters
BOSTON, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.